A polymorphism in the interleukin-10 promoter affects the course of disease in patients with clear-cell renal carcinoma.

[1]  F. Garrido,et al.  High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. , 2007, Human immunology.

[2]  Javier Martín,et al.  Influence of interleukin 10 promoter polymorphisms in susceptibility to giant cell arteritis in Northwestern Spain. , 2007, The Journal of rheumatology.

[3]  Wan-Wan Lin,et al.  A cytokine-mediated link between innate immunity, inflammation, and cancer. , 2007, The Journal of clinical investigation.

[4]  A. Ben-Baruch.  The multifaceted roles of chemokines in malignancy , 2006, Cancer and Metastasis Reviews.

[5]  Astrid Dempfle,et al.  TNF-α, TNF-β, IL-6, and IL-10 Polymorphisms in Patients with Lung Cancer , 2005, Disease markers.

[6]  F. Marincola,et al.  Interleukin‐10 and the immune response against cancer: a counterpoint , 2005, Journal of leukocyte biology.

[7]  J. Lam,et al.  Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. , 2005, The Journal of urology.

[8]  A. Mantovani,et al.  Smoldering and polarized inflammation in the initiation and promotion of malignant disease. , 2005, Cancer cell.

[9]  H. Pandha,et al.  An interleukin-10 promoter polymorphism may influence tumor development in renal cell carcinoma. , 2005, The Journal of urology.

[10]  C. Gutiérrez,et al.  Influence of interleukin-10 genetic polymorphism on survival rates in melanoma patients with advanced disease , 2005, Melanoma research.

[11]  G. Salles,et al.  Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. , 2004, Blood.

[12]  C. D. Krause,et al.  Interleukin-10 and related cytokines and receptors. , 2004, Annual review of immunology.

[13]  Luc J. Smink,et al.  Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease , 2003, Nature.

[14]  C. Gutiérrez,et al.  Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms1 , 2003, Transplantation.

[15]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[16]  R. Eeles,et al.  Influence of cytokine gene polymorphisms on the development of prostate cancer. , 2002, Cancer research.

[17]  Andrew V. Nguyen,et al.  Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy , 2001, The Journal of experimental medicine.

[18]  A. Bateman,et al.  IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma , 2001, Genes and Immunity.

[19]  J. Satsangi,et al.  Cytokine (TNFα, LTα and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies , 2000, Genes and Immunity.

[20]  S. Rosenberg,et al.  Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. , 1999, Journal of immunotherapy.

[21]  M. Bar‐eli,et al.  Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[22]  R. Westendorp,et al.  Interleukin 10 secretion in relation to human IL-10 locus haplotypes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Barnes,et al.  Haplotype associated with low interleukin-10 production in patients with severe asthma , 1998, The Lancet.

[24]  P. Musiani,et al.  Local release of interleukin-10 by transfected mouse adenocarcinoma cells exhibits pro- and anti-inflammatory activity and results in a delayed tumor rejection. , 1998, European cytokine network.

[25]  P. Sasieni.  From genotypes to genes: doubling the sample size. , 1997, Biometrics.

[26]  L. Abraham,et al.  The −308 tumor necrosis factor-α promoter polymorphism effects transcription , 1997 .

[27]  M. Lazarus,et al.  An investigation of polymorphism in the interleukin-10 gene promoter. , 1997, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[28]  C. Bucana,et al.  Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  E. Maxwell,et al.  Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism , 1996, The Journal of experimental medicine.

[30]  T. Beaty,et al.  Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. , 1996, Journal of the National Cancer Institute.

[31]  P. Polverini,et al.  Induction of Neovascularization and Nonlymphoid Mesenchymal Cell Proliferation by Macrophage Cell Lines , 1985, Journal of leukocyte biology.

[32]  E. Nkenke,et al.  The interleukin-10 (-1082A/G) polymorphism is strongly associated with increased risk for oral squamous cell carcinoma. , 2008, Anticancer research.

[33]  M. Rose-Zerilli,et al.  Interleukin-10 Polymorphisms, Cancer Susceptibility and Prognosis , 2005, Familial Cancer.